Advaxis Inc. (OTC: ADXS), a clinical-stage biotechnology company engaged in the development of next generation of immunotherapies for cancer and infectious diseases, has seen a sharp rise in its shares in trading today.
ADXS shares are currently trading 15.56% higher at $0.104 on above average volume of 3.62 million.
Advaxis shares are gaining momentum after the company said that its ADXS-PSA construct caused substantial tumor regression in preclinical prostate cancer study. ADXS-PSA is Advaxis’s immunotherapy designed to target the PSA antigen associated with prostate cancer.
The preclinical research was conducted in collaboration with Dr. Chandan Guha and his laboratory at Montefiore Medical Center in Bronx, New York. The main goal of the study was to identify if the combination of ADXS-PSA immunotherapy and radiation therapy could improve upon the efficacy of either immunotherapy alone or radiation therapy alone in the treatment of mice bearing PSA-expressing TPSA23 tumors.
Recent Comments